Skip to main content

Waldenstrom's Macroglobulinemia

7
Pipeline Programs
9
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
1
2
LBH589Phase 2
RAD001Phase 2
EverolimusPhase 1/2
ETS
ETSMO - Rolla
1 program
1
Bortezomib-Rituximab-BendamustinePhase 21 trial
Active Trials
NCT02371148Completed38Est. Jul 2020
Prevail Therapeutics
1 program
1
EnzastaurinPhase 2
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
GS-1101Phase 2
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
IbrutinibPhase 2Small Molecule1 trial
Active Trials
NCT02604511Completed31Est. Nov 2022
X4 Pharmaceuticals
1 program
MavorixaforPHASE_11 trial
Active Trials
NCT04274738Completed16Est. Oct 2022
Bristol Myers Squibb
1 program
UlocuplumabPHASE_1Monoclonal Antibody3 trials
Active Trials
NCT02666209No Longer Available
NCT03225716Terminated13Est. Dec 2022
NCT02472977Terminated61Est. Jan 2017
Genentech
GenentechCA - Oceanside
1 program
CC-5103PHASE_2
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
EnzastaurinPHASE_21 trial
Active Trials
NCT00718419Completed56Est. Aug 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieIbrutinib
ETSBortezomib-Rituximab-Bendamustine
Eli Lilly and CompanyEnzastaurin
Bristol Myers SquibbUlocuplumab
X4 PharmaceuticalsMavorixafor
Bristol Myers SquibbUlocuplumab

Clinical Trials (7)

Total enrollment: 215 patients across 7 trials

NCT02604511AbbVieIbrutinib

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Start: Jan 2016Est. completion: Nov 202231 patients
Phase 2Completed
NCT02371148ETSBortezomib-Rituximab-Bendamustine

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's

Start: Jun 2014Est. completion: Jul 202038 patients
Phase 2Completed
NCT00718419Eli Lilly and CompanyEnzastaurin

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

Start: Jul 2008Est. completion: Aug 201256 patients
Phase 2Completed
NCT02472977Bristol Myers SquibbUlocuplumab

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Start: Jul 2015Est. completion: Jan 201761 patients
Phase 1/2Terminated
NCT04274738X4 PharmaceuticalsMavorixafor

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Start: Apr 2020Est. completion: Oct 202216 patients
Phase 1Completed
NCT03225716Bristol Myers SquibbUlocuplumab

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Start: Oct 2017Est. completion: Dec 202213 patients
Phase 1Terminated
NCT02666209Bristol Myers SquibbUlocuplumab

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

N/ANo Longer Available

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.